|
Volumn 51, Issue 3 SUPPL. 2, 2001, Pages 58-59
|
Gynecology Cancer Working Group
a a a a a a a a a a a a a a a a a a a a more..
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
AMIFOSTINE;
CISPLATIN;
FLUOROPYRIMIDINE;
FLUOROURACIL;
TUMOR MARKER;
BRACHYTHERAPY;
CANCER ADJUVANT THERAPY;
CANCER CHEMOTHERAPY;
CANCER RADIOTHERAPY;
CANCER RECURRENCE;
CANCER SURVIVAL;
CLINICAL TRIAL;
ENDOMETRIUM CANCER;
HUMAN;
MORBIDITY;
MULTIMODALITY CANCER THERAPY;
PRIORITY JOURNAL;
QUALITY OF LIFE;
SHORT SURVEY;
SURVIVAL RATE;
TREATMENT OUTCOME;
UTERINE CERVIX CANCER;
ARTICLE;
FEMALE;
FEMALE GENITAL TRACT TUMOR;
FINANCIAL MANAGEMENT;
FORECASTING;
METHODOLOGY;
ONCOLOGY;
ORGANIZATION;
ORGANIZATION AND MANAGEMENT;
PROFESSIONAL STANDARD;
CLINICAL TRIALS;
COMBINED MODALITY THERAPY;
FEMALE;
FORECASTING;
GENITAL NEOPLASMS, FEMALE;
HUMANS;
ORGANIZATIONAL OBJECTIVES;
PROFESSIONAL STAFF COMMITTEES;
RADIATION ONCOLOGY;
RESEARCH DESIGN;
RESEARCH SUPPORT;
|
EID: 0034782556
PISSN: 03603016
EISSN: None
Source Type: Journal
DOI: 10.1016/S0360-3016(01)01783-7 Document Type: Article |
Times cited : (1)
|
References (0)
|